Prescription medicine
Netupitant and palonosetron Brand names: Akynzeo
Netupitant and palonosetron (Akynzeo) is a prescription medicine with an FDA approval on record since 2014. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: netupitant and palonosetron labels on DailyMed; the NDA 205718 record on Drugs@FDA; every netupitant and palonosetron label on DailyMed.
Highlights of the record
no current FDA label; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
The label in openFDA carries no indications section.
Forms and strengths
- 300 mg / 0.5 mg
Capsule.
On the market
- Earliest approval on file
- October 10, 2014 Akynzeo, Helsinn Hlthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- September 25, 2035 Akynzeo capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,139 through July 30, 2026
Is there a generic for netupitant and palonosetron (Akynzeo)?
No generic netupitant and palonosetron is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 12 patents for Akynzeo capsules: the compound patent runs to September 25, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for netupitant and palonosetron?
The FDA Adverse Event Reporting System holds 1,139 reports that list netupitant and palonosetron among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 159 are coded as a death and 594 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other serotonin-3 receptor antagonists
- the pharmacologic class, with prices and generics
- Netupitant and palonosetron side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other